Big Pharma’s $300 Billion Patent Problem Fuels Biotech Deals

Big Pharma has a $300 billion problem, and biotech developers with promising drugs are becoming the fix. Major drugmakers are spending at a pace not seen since 2019 to replace medicines that will soon lose patent protection.
Key Takeaways:
- Big Pharma faces $300 billion in expiring drug patents through the decade.
- Total biopharma deal value could top $250 billion in 2026, the busiest year since 2019.
- SBIO’s June rebalance added 37 names ahead of a wave of trial and takeover news.
According to PwC’s midyear deals outlook, more than $300 billion in branded pharmaceutical revenue will lose patent protection by the end of the decade. That loss, known as a loss of exclusivity, is pushing large drugmakers to buy new drug pipelines rather than build them in-house.
ALPS Advisors’ July spotlight shows the ALPS Medical Breakthroughs ETF (SBIO) holds mid-size biotech developers in that same targeted stage. That focus put the fund in the middle of June’s biggest headline. AbbVie Inc. (ABBV) agreed to pay $10.9 billion in cash for Apogee Therapeutics, Inc. (APGE), then SBIO’s largest holding.
See more: Biotech Gives SBIO Its Best Month Since 2023
PwC’s report also found large pharmaceutical companies are avoiding blockbuster mergers that draw heavy regulatory scrutiny. Midcap biotech bolt-on deals have become the sweet spot for dealmaking this year instead.
That shift is already showing up in the numbers. Total biopharma deal value is on pace to top $250 billion in 2026, according to PitchBook data cited by ALPS Advisors. That would mark the industry’s strongest year since 2019.
Regulatory news added another tailwind. On June 17, the FDA signaled a more flexible approval path for serious and rare diseases, according to ALPS Advisors. Days later, Definium Therapeutics Inc. (DFTX) raised an upsized $700 million in stock to fund its own drug submission. It chose capital over a buyout.
Inside SBIO’s Biotech Screening Rulesss
SBIO tracks an index limited to U.S. biotech companies worth between $200 million and $5 billion, according to ALPS Advisors. Each company must have a drug in Phase II or Phase III FDA trials. Each must also hold enough cash to fund about two years of operations.
Broader benchmarks such as the NASDAQ Biotechnology Index lean toward the large-cap companies writing acquisition checks, according to ALPS Advisors. SBIO’s index sits on the other side of those deals, holding the smaller companies, which are usually the ones getting bought.
Twice a year, the fund’s index rebalances to keep pace. Its June 18 update added 37 companies and dropped 15, according to ALPS Advisors. That turnover brought Definium into the fund just four days before its trial results sent shares up more than 90%.
For more news, information, and strategy, visit the ETF Building Blocks Content Hub.
VettaFi LLC (“VettaFi”) is the index provider for SBIO, for which it receives an index licensing fee. However, SBIO is not issued, sponsored, endorsed, or sold by VettaFi, and VettaFi has no obligation or liability in connection with the issuance, administration, marketing, or trading of SBIO.

Facts Only

* Big Pharma faces $300 billion in expiring drug patents through the decade.
* Total biopharma deal value could top $250 billion in 2026.
* The loss of exclusivity is pushing large drugmakers to buy new drug pipelines rather than build them in-house.
* AbbVie Inc. agreed to pay $10.9 billion cash for Apogee Therapeutics, Inc. in a transaction involving SBIO’s largest holding.
* The ALPS Medical Breakthroughs ETF (SBIO) tracks mid-size biotech developers valued between $200 million and $5 billion.
* Each company in SBIO must have a drug in Phase II or Phase III FDA trials and sufficient cash for two years of operations.
* SBIO’s June rebalance added 37 names and dropped 15 companies.
* Definium Therapeutics Inc. raised $700 million in stock to fund its own drug submission following an FDA signal change.

Executive Summary

Large pharmaceutical companies are facing a challenge due to patent expirations, with over $300 billion in branded pharmaceutical revenue projected to lose patent protection by the end of the decade, leading drugmakers to seek new pipelines. This loss of exclusivity is driving large drugmakers toward acquiring new drug pipelines instead of developing them internally. The biopharma deal market is also expanding; total deal value is expected to reach $250 billion in 2026, which is the busiest year since 2019. A specific focus on mid-size biotech developers is evident in investment vehicles like the ALPS Medical Breakthroughs ETF (SBIO). Furthermore, regulatory shifts, such as the FDA signaling a more flexible approval path for serious and rare diseases, have influenced corporate strategy, leading some entities to prioritize funding drug submissions over immediate buyouts.

Full Take

The narrative positions the transition from internal R&D to external acquisition as a necessary response to patent erosion, framing biotech dealmaking as the new engine of pharmaceutical value generation. The pattern suggests that market instability caused by intellectual property timelines creates a systemic pressure favoring bolt-on deals among midcap biotechs, which possess valuable, albeit nascent, pipeline assets. The shift away from blockbuster mergers—which attract heavy regulatory scrutiny—to smaller bolt-on acquisitions reflects an attempt to navigate the risk landscape while still capitalizing on growth potential. The focus on indices like SBIO, which target companies in the clinical trial stage, implies a systemic preference for capturing value at inflection points rather than fully mature assets, which often generate greater volatility and incentive for swift transactions. The flexibility provided by regulatory shifts further amplifies this trend, creating opportunities for companies to pursue funding pathways that bypass traditional, slow development cycles. The key implication is how the structure of market incentives—patents versus acquisition velocity—redefines the role and valuation of early-stage innovation within the larger pharmaceutical ecosystem. What factors influence whether established entities choose internalization or acquisition when patent timelines are uncertain? How does regulatory flexibility alter the perceived risk calculation for acquiring assets in a high-growth, pre-commercial biotech space?

Sentinel — Human

Confidence

The text functions as a synthesized news report, drawing on verifiable statistics from named sources to explain complex biotech market trends.

Signals Detected

Moderate sentence length variance; use of direct factual linkage rather than purely synthetic flow.

The text flows logically by connecting disparate data points (patents, deals, ETF activity) but lacks an overtly passionate or proprietary voice.

Effective use of cited entities (PwC, ALPS Advisors, PitchBook) and specific dates/figures suggests reliance on real external reporting rather than pure internal generation.

The structure mimics standard financial/industry reporting; the inclusion of a formal disclaimer at the end is typical of source aggregation.

Human Indicators

Specific, layered citation of multiple external sources (PwC, ALPS Advisors, PitchBook) indicates journalistic research structure.

The narrative pivots effectively between high-level industry problems and specific ETF mechanics, showing an analytical structuring common in financial reporting.